Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Verubulin with RT and TMZ in newly diagnosed GBM
NCT01285414Phase 2Completed
- Sponsor
- Myrexis, Inc.
- Start
- Dec 2010
- Primary completion
- Mar 2012
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of verubulin in glioblastoma multiforme (GBM) (2 arms), sponsored by Myrexis, Inc. Primary endpoints: Safety at 14 weeks and Progression-Free Survival at 9 months. Started Dec 2010; status: completed.
02
Drugs
verubulin
03
Conditions
glioblastoma multiforme (GBM)
Beyond the preview
Go deeper on NCT01285414.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01285414.